Pathology consultation on prostate-specific antigen testing

American Journal of Clinical Pathology

Volumn 142, Issue 1, 2014, Pages 7-15

  Noguez, Jaime H ^a   Fantz, Corinne R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Prostate cancer; Prostate specific antigen; Screening

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIANDROGEN; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; ANDROGEN DEPRIVATION THERAPY; ANTIBIOTIC THERAPY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER SCREENING; CASE REPORT; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CONSULTATION; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DIGITAL RECTAL EXAMINATION; GENERAL PRACTITIONER; GLEASON SCORE; HERBAL MEDICINE; HUMAN; IMAGE GUIDED BIOPSY; LIVER BIOPSY; LIVER METASTASIS; LOWER URINARY TRACT SYMPTOM; LUNG METASTASIS; LUNG NODULE; MALE; MIDDLE AGED; NEEDLE BIOPSY; NOMOGRAM; PERINEURAL INVASION; PHYSICAL EXAMINATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE VOLUME; PROSTATITIS; REVIEW; RISK BENEFIT ANALYSIS; SELF MEDICATION; SENSITIVITY AND SPECIFICITY; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT RESPONSE; URINE CYTOLOGY; UROLOGIST; VARICOCELE; WATCHFUL WAITING;

PROSTATE CANCER; PROSTATE-SPECIFIC ANTIGEN; SCREENING;

EARLY DETECTION OF CANCER; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 84904552996     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPU6OOKL9JHEUR     Document Type: Review

References (64)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. Fleshner N, Lawrentschuk N. Risk of developing prostate cancer in the future: overview of prognostic biomarkers. Urology. 2009;73(suppl):S21-S27.
3. Schroder F, Roobol M, Andriole G, et al. Defining increased future risk for prostate cancer: evidence from a population based screening cohort. J Urol. 2009;181:69-74.
4. Lilja H, Christensson A, Dahlen U, et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem. 1991;37:1618-1625. (Pubitemid 21905228)
5. Stenman UH, Leinonen J, Alfthan H, et al. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 1991;51:222-226.
6. Zhou AM, Tewari PC, Bluestein BI, et al. Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays. Clin Chem. 1993;39:2483-2491. (Pubitemid 24008233)
7. Sensabaugh GF. Isolation and characterization of a semen-specific protein from human seminal plasma: a potential new marker for semen identification. J Forensic Sci. 1978;23:106-115. (Pubitemid 8275289)
8. Wang MC, Valenzuela LA, Murphy GP, et al. Purification of a human prostate specific antigen. Invest Urol. 1979;17:159-163. (Pubitemid 10132507)
9. Papsidero LD, Wang MC, Valenzuela LA, et al. A prostate antigen in sera of prostatic cancer patients. Cancer Res. 1980;40:2428-2432. (Pubitemid 10082262)
10. Etzioni R, Tsodikov A, Mariotto A, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2008;19:175-181.
11. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156-1161.
12. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151:1283-1290. (Pubitemid 24121936)
13. Catalona WJ, Hudson MA, Scardino PT, et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol. 1994;152:2037-2042. (Pubitemid 24354722)
14. Lu-Yao GL, Friedman M, Yao SL. Use of radical prostatectomy among Medicare beneficiaries before and after the introduction of prostate specific antigen testing. J Urol. 1997;157:2219-2222.
15. Lu-Yao GL, Greenberg ER. Changes in prostate cancer incidence and treatment in USA. Lancet. 1994;343:251-254. (Pubitemid 24039623)
16. Potosky AL, Miller BA, Albertsen PC, et al. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273:548-552.
17. Mettlin C, Jones G, Averette H, et al. Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers. CA Cancer J Clin. 1993;43:42-46. (Pubitemid 23049042)
18. American Urological Association. Early detection of prostate cancer and use of transrectal ultrasound. American Urological Association 1992 Policy Statement Book. Baltimore, MD: Williams & Wilkins; 1992.
19. American College of Physicians. Screening for prostate cancer. Ann Intern Med. 1997;126:480-484.
20. United States Preventive Services Task Force. Guide to Clinical Preventive Services. 2nd ed. Baltimore, MD: Williams & Wilkins; 1996.
21. National Cancer Institute. PDQ® prostate cancer screening [database on the Internet]. Available at: http://cancer.gov/cancertopics/pdq/screening/ prostate/HealthProfessional. Accessed March 20, 2014.
22. Slev PR, La'ulu SL, Roberts WL. Intermethod differences in results for total PSA, free PSA, and percentage of free PSA. Am J Clin Pathol. 2008;129:952-958.
23. Puustinen J, Lahteenmaki R, Polo-Kantola P, et al. Effect of withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotic agents on cognition in older adults. Eur J Clin Pharmacol. 2013;70:319-329.
24. Stenman UH, Koivunen E, Itkonen O. Biology and function of tumor-associated trypsin inhibitor, TATI. Scand J Clin Lab Invest Suppl. 1991;207:5-9.
25. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004;350:2239-2246.
26. Prensner JR, Rubin MA, Wei JT, et al. Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med. 2012;4:127rv3.
27. Killick E, Bancroft E, Kote-Jarai Z, et al. Beyond prostatespecific antigen - future biomarkers for the early detection and management of prostate cancer. Clin Oncol (R Coll Radiol). 2012;24:545-555.
28. Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60:70-98.
29. Partin MR, Powell AA, Burgess DJ, et al. Adding postal follow-up to a web-based survey of primary care and gastroenterology clinic physician chiefs improved response rates but not response quality or representativeness [published online ahead of print December 5, 2013]. Eval Health Prof. 2013.
30. Benson MC, Whang IS, Olsson CA, et al. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol. 1992;147:817-821.
31. Andriole GL, Telle WB, Coplen DE, et al. PSA index (PSAI) as a predictor of prostate cancer in men with persistent serum PSA elevation. J Urol. 1992;147:387A.
32. Benson MC, Whang IS, Pantuck A, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol. 1992;147:815-816.
33. Catalona WJ, Richie JP, deKernion JB, et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol. 1994;152:2031-2036. (Pubitemid 24354721)
34. Smith DS, Catalona WJ. Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol. 1994;152:1163-1167. (Pubitemid 24283458)
35. Carter HB, Ferrucci L, Kettermann A, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst. 2006;98:1521-1527. (Pubitemid 44680903)
36. Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992;267:2215-2220.
37. Riehmann M, Rhodes PR, Cook TD, et al. Analysis of variation in prostate-specific antigen values. Urology. 1993;42:390-397. (Pubitemid 23314330)
38. Carter HB, Partin AW, Luderer AA, et al. Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology. 1997;49:379-384. (Pubitemid 27138680)
39. Hoffman RM, Clanon DL, Littenberg B, et al. Using the free-to-total prostate-specific antigen ratio to detect prostate cancer in men with nonspecific elevations of prostate-specific antigen levels. J Gen Intern Med. 2000;15:739-748.
40. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998;279:1542-1547. (Pubitemid 28233009)
41. Piironen T, Pettersson K, Suonpaa M, et al. In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples. Urology. 1996;48:81-87. (Pubitemid 26425542)
42. Hominger W, Cheli CD, Babaian RJ, et al. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. Urology. 2002;60:31-35.
43. Khan SK, Malviya A, Muller SD, et al. Reduced short-term complications and mortality following enhanced recovery primary hip and knee arthroplasty: results from 6,000 consecutive procedures. Acta Orthop. 2013;85:26-31.
44. Partin AW, Brawer MK, Bartsch G, et al. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol. 2003;170:1787-1791. (Pubitemid 37254929)
45. Jung K, Elgeti U, Lein M, et al. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer? Clin Chem. 2000;46:55-62. (Pubitemid 30090960)
46. Mikolajczyk SD, Marks LS, Partin AW, et al. Free prostate-specific antigen in serum is becoming more complex. Urology. 2002;59:797-802. (Pubitemid 34522163)
47. Canto El, Singh H, Shariat SF, et al. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology. 2004;63:905-910; discussion 910-901.
48. Sokoll LJ, Sanda MG, Feng Z, et al. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev. 2010;19:1193-1200.
49. Sokoll LJ, Wang Y, Feng Z, et al. [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol. 2008;180:539-543; discussion 543.
50. Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol. 2011;185:1650-1655.
51. Le BV, Griffin CR, Loeb S, et al. [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol. 2010;183:1355-1359.
52. Stenman G, Sahlin P, Mark J, et al. Structural alterations of the c-mos locus in benign pleomorphic adenomas with chromosome abnormalities of 8q12. Oncogene. 1991;6:1105-1108. (Pubitemid 21924195)
53. Stenman G, Sandros J, Nordkvist A, et al. Expression of the ERBB2 protein in benign and malignant salivary gland tumors. Genes Chromosomes Cancer. 1991;3:128-135.
54. Howlander N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2010. Bethesda, MD: National Cancer Institute. Available at http://seer.cancer.gov/csr/1975-2010/, based on November 2012 SEER data submission posted to the SEER website, April 2013. Accessed March 20, 2014.
55. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-1328.
56. Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;366:981-990.
57. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11:725-732.
58. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364:1708-1717.
59. Andriole GL, Crawford ED, Grubb RL, 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310-1319.
60. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367:203-213.
61. Loeb S, Vellekoop A, Ahmed HU, et al. Systematic review of complications of prostate biopsy. Eur Urol. 2013.
62. Duffy MJ. Use of biomarkers in screening for cancer. J Int Fed Clin Chem Lab Med. 2010. Available at http://www.ifcc.org/ejifcc/vol21. Accessed March 20, 2014.
63. Pinsky PF, Blacka A, Kramer BS, et al. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials. 2010;7:303-311.
64. Aleksic I, Mouraviev V, Albala D. Recent developments in prostate cancer screening guidelines. J Cancer Sci Ther. 2013;S7:005.